Brigham and Women's Hospital
Brigham and Women's Hospital was founded at the end of the 19th century and occupies space adjacent to the Quadrangle of Harvard Medical School. Like Massachusetts General Hospital and Beth Israel Deaconess Medical Center, it, too, is a full-service hospital with about 700 beds and a full spectrum of cancer care activities. For more than 35 years, it has been a close ally of Dana-Farber Cancer Institute in a number of clinical research endeavors, and, with MGH, it is a partner of DFCI in Dana-Farber / Partners Cancer Care. BWH houses all of the licensed beds of DFCI, which no longer maintains a separate in-patient service on Dana-Farber property.
BWH, like MGH, also maintains an active and broad portfolio of cancer research activity. It is a Harvard center of excellence in cancer imaging, endothelial cell research, brain tumor research, and in viral oncology. BWH is a national center for research on Epstein-Barr Virus under the direction of Dr. Elliott Kieff, who serves as Deputy Associate Director for Basic Science. It also operates a special laboratory on its campus (the Channing Laboratory) which houses the activities of a major population sciences-associated cancer research unit, the Nurses Health Study, directed by Dr. Frank Speizer, who serves as Associate Director for Core Facilities.
Scientific Leadership of BWH
Aster, Jon C.
Berkowitz, Ross S.
Bertagnolli, Monica M.
Black, Peter McLaren
Buring, Julie
Colditz, Graham A.
Cramer, Daniel
D'Amico, Anthony
Fletcher, Christopher
Gilliland, Dwight Gary
Kupper, Thomas S.
Kwiatkowski, David J.
Morton, Cynthia C.
Rubin, Mark
Speizer, Frank E.
Institutional Administrator of BWH
Lissa Olbeter
(617) 525-4304
lobeter@partners.org





